The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice

M R Nangle, M A Cotter, Norman E Cameron

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Calpains, a superfamily of Ca2+-activated proteases, are associated with an array of physiological and pathological events, including susceptibility to diabetes. Recently, increased calpain activity has been linked to reduced endothelium-derived nitric oxide-mediated vasodilatation in diabetes. However, a similar mechanism for neuronal-derived nitric oxide has not been examined. Thus, the aim was to investigate effects of the calpain inhibitor A-705253, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethyl-aminomethylphenyl)ethen-1-yl]benzamide, on nitrergic neurovascular function in diabetic mice. Diabetes was induced by streptozotocin; duration was 6 weeks. Intervention A-705253 treatment (30 mg/kg/day) was given for 2 weeks following 4 weeks of untreated diabetes. After 6 weeks of diabetes, corpus cavemosa were isolated in organ baths for measurement of agonist- and electrical stimulation-evoked smooth muscle tensions. Adrenergic nerve- and phenylephrine-mediated contractions were not altered by diabetes or calpain inhibition. In contrast, maximum nitrergic nerve-mediated relaxation of phenylqphrine-precontracted cavernosum was approximately 29% reduced by diabetes (P < 0.001). This neurological deficit was 66% corrected by A-705253 treatment (P < 0.05). Maximum nitric oxide-mediated endothelium-dependent relaxation to acetylcholine was attenuated approximately 39% by diabetes (P < 0.01). Similarly, maximum endothelium-independent relaxation to the nitric oxide donor, sodium nitroprusside, was blunted approximately 23% by diabetes (P < 0.001). A-705253 treatment partially improved endothelium-dependent relaxation to acetylcholine but had no effect on the deficit in response to nitroprusside. The data suggest that calpain contributes to the aetiology of diabetic nitrergic autonomic neuropathy and endothelial dysfunction, which may provide a novel therapeutic target for neurovascular complications. (c) 2006 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalEuropean Journal of Pharmacology
Volume538
DOIs
Publication statusPublished - 2006

Keywords

  • calpain
  • corpus cavernosum
  • diabetes
  • endothelium
  • erectile dysfunction
  • neuropathy
  • nitric oxide
  • smooth muscle
  • NITRIC-OXIDE SYNTHASE
  • CORPUS CAVERNOSUM
  • SMOOTH-MUSCLE
  • ENDOTHELIAL DYSFUNCTION
  • RELAXATION
  • MELLITUS
  • RATS
  • HEAT-SHOCK-PROTEIN-90
  • ASSOCIATION
  • ACTIVATION

Cite this

The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice. / Nangle, M R ; Cotter, M A ; Cameron, Norman E.

In: European Journal of Pharmacology, Vol. 538, 2006, p. 148-153.

Research output: Contribution to journalArticle

Nangle, M R ; Cotter, M A ; Cameron, Norman E. / The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice. In: European Journal of Pharmacology. 2006 ; Vol. 538. pp. 148-153.
@article{68055d74989949f88867d74a7da05adc,
title = "The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice",
abstract = "Calpains, a superfamily of Ca2+-activated proteases, are associated with an array of physiological and pathological events, including susceptibility to diabetes. Recently, increased calpain activity has been linked to reduced endothelium-derived nitric oxide-mediated vasodilatation in diabetes. However, a similar mechanism for neuronal-derived nitric oxide has not been examined. Thus, the aim was to investigate effects of the calpain inhibitor A-705253, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethyl-aminomethylphenyl)ethen-1-yl]benzamide, on nitrergic neurovascular function in diabetic mice. Diabetes was induced by streptozotocin; duration was 6 weeks. Intervention A-705253 treatment (30 mg/kg/day) was given for 2 weeks following 4 weeks of untreated diabetes. After 6 weeks of diabetes, corpus cavemosa were isolated in organ baths for measurement of agonist- and electrical stimulation-evoked smooth muscle tensions. Adrenergic nerve- and phenylephrine-mediated contractions were not altered by diabetes or calpain inhibition. In contrast, maximum nitrergic nerve-mediated relaxation of phenylqphrine-precontracted cavernosum was approximately 29{\%} reduced by diabetes (P < 0.001). This neurological deficit was 66{\%} corrected by A-705253 treatment (P < 0.05). Maximum nitric oxide-mediated endothelium-dependent relaxation to acetylcholine was attenuated approximately 39{\%} by diabetes (P < 0.01). Similarly, maximum endothelium-independent relaxation to the nitric oxide donor, sodium nitroprusside, was blunted approximately 23{\%} by diabetes (P < 0.001). A-705253 treatment partially improved endothelium-dependent relaxation to acetylcholine but had no effect on the deficit in response to nitroprusside. The data suggest that calpain contributes to the aetiology of diabetic nitrergic autonomic neuropathy and endothelial dysfunction, which may provide a novel therapeutic target for neurovascular complications. (c) 2006 Elsevier B.V. All rights reserved.",
keywords = "calpain, corpus cavernosum, diabetes, endothelium, erectile dysfunction, neuropathy, nitric oxide, smooth muscle, NITRIC-OXIDE SYNTHASE, CORPUS CAVERNOSUM, SMOOTH-MUSCLE, ENDOTHELIAL DYSFUNCTION, RELAXATION, MELLITUS, RATS, HEAT-SHOCK-PROTEIN-90, ASSOCIATION, ACTIVATION",
author = "Nangle, {M R} and Cotter, {M A} and Cameron, {Norman E}",
year = "2006",
doi = "10.1016/j.ejphar.2006.03.068",
language = "English",
volume = "538",
pages = "148--153",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice

AU - Nangle, M R

AU - Cotter, M A

AU - Cameron, Norman E

PY - 2006

Y1 - 2006

N2 - Calpains, a superfamily of Ca2+-activated proteases, are associated with an array of physiological and pathological events, including susceptibility to diabetes. Recently, increased calpain activity has been linked to reduced endothelium-derived nitric oxide-mediated vasodilatation in diabetes. However, a similar mechanism for neuronal-derived nitric oxide has not been examined. Thus, the aim was to investigate effects of the calpain inhibitor A-705253, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethyl-aminomethylphenyl)ethen-1-yl]benzamide, on nitrergic neurovascular function in diabetic mice. Diabetes was induced by streptozotocin; duration was 6 weeks. Intervention A-705253 treatment (30 mg/kg/day) was given for 2 weeks following 4 weeks of untreated diabetes. After 6 weeks of diabetes, corpus cavemosa were isolated in organ baths for measurement of agonist- and electrical stimulation-evoked smooth muscle tensions. Adrenergic nerve- and phenylephrine-mediated contractions were not altered by diabetes or calpain inhibition. In contrast, maximum nitrergic nerve-mediated relaxation of phenylqphrine-precontracted cavernosum was approximately 29% reduced by diabetes (P < 0.001). This neurological deficit was 66% corrected by A-705253 treatment (P < 0.05). Maximum nitric oxide-mediated endothelium-dependent relaxation to acetylcholine was attenuated approximately 39% by diabetes (P < 0.01). Similarly, maximum endothelium-independent relaxation to the nitric oxide donor, sodium nitroprusside, was blunted approximately 23% by diabetes (P < 0.001). A-705253 treatment partially improved endothelium-dependent relaxation to acetylcholine but had no effect on the deficit in response to nitroprusside. The data suggest that calpain contributes to the aetiology of diabetic nitrergic autonomic neuropathy and endothelial dysfunction, which may provide a novel therapeutic target for neurovascular complications. (c) 2006 Elsevier B.V. All rights reserved.

AB - Calpains, a superfamily of Ca2+-activated proteases, are associated with an array of physiological and pathological events, including susceptibility to diabetes. Recently, increased calpain activity has been linked to reduced endothelium-derived nitric oxide-mediated vasodilatation in diabetes. However, a similar mechanism for neuronal-derived nitric oxide has not been examined. Thus, the aim was to investigate effects of the calpain inhibitor A-705253, N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethyl-aminomethylphenyl)ethen-1-yl]benzamide, on nitrergic neurovascular function in diabetic mice. Diabetes was induced by streptozotocin; duration was 6 weeks. Intervention A-705253 treatment (30 mg/kg/day) was given for 2 weeks following 4 weeks of untreated diabetes. After 6 weeks of diabetes, corpus cavemosa were isolated in organ baths for measurement of agonist- and electrical stimulation-evoked smooth muscle tensions. Adrenergic nerve- and phenylephrine-mediated contractions were not altered by diabetes or calpain inhibition. In contrast, maximum nitrergic nerve-mediated relaxation of phenylqphrine-precontracted cavernosum was approximately 29% reduced by diabetes (P < 0.001). This neurological deficit was 66% corrected by A-705253 treatment (P < 0.05). Maximum nitric oxide-mediated endothelium-dependent relaxation to acetylcholine was attenuated approximately 39% by diabetes (P < 0.01). Similarly, maximum endothelium-independent relaxation to the nitric oxide donor, sodium nitroprusside, was blunted approximately 23% by diabetes (P < 0.001). A-705253 treatment partially improved endothelium-dependent relaxation to acetylcholine but had no effect on the deficit in response to nitroprusside. The data suggest that calpain contributes to the aetiology of diabetic nitrergic autonomic neuropathy and endothelial dysfunction, which may provide a novel therapeutic target for neurovascular complications. (c) 2006 Elsevier B.V. All rights reserved.

KW - calpain

KW - corpus cavernosum

KW - diabetes

KW - endothelium

KW - erectile dysfunction

KW - neuropathy

KW - nitric oxide

KW - smooth muscle

KW - NITRIC-OXIDE SYNTHASE

KW - CORPUS CAVERNOSUM

KW - SMOOTH-MUSCLE

KW - ENDOTHELIAL DYSFUNCTION

KW - RELAXATION

KW - MELLITUS

KW - RATS

KW - HEAT-SHOCK-PROTEIN-90

KW - ASSOCIATION

KW - ACTIVATION

U2 - 10.1016/j.ejphar.2006.03.068

DO - 10.1016/j.ejphar.2006.03.068

M3 - Article

VL - 538

SP - 148

EP - 153

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -